A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.

Shunsuke FunazakiMasashi YoshidaHodaka YamadaMasafumi KakeiMasanobu KawakamiShuichi NagashimaKazuo HaraKatsuya Dezaki

Published in: Journal of diabetes investigation (2021)

Imeglimin may activate TRPM2 channels in β-cells via the production of NAD+ /cADPR, leading to the potentiation of GSIS. Developing approaches to stimulate cADPR-TRPM2 signaling provides a potential therapeutic tool to treat type 2 diabetes.

Keyphrases

type diabetes
induced apoptosis
cell cycle arrest
cardiovascular disease
glycemic control
insulin resistance
oxidative stress
skeletal muscle